Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma

Tumori

Volumn 96, Issue 1, 2010, Pages 60-64

  Muni, Roberta ^a   Minniti, Giuseppe ^a,b   Lanzetta, Gaetano ^b   Caporello, Paola ^a   Frati, Alessandro ^b   Enrici, Maurizio Maurizi ^a   Marchetti, Paolo ^a   Enrici, Riccardo Maurizi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Chemotherapy; Elderly; Glioblastoma; Prognostic factors; Radiotherapy; Temozolomide

Indexed keywords

STEROID; TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RASH; SHORT COURSE THERAPY; SOMNOLENCE; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 77950817976     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1700/479.5652     Document Type: Article

References (21)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352: 987-996, 2005.
2. Bauman GS, Gaspar LE, Fisher BJ,Halperin EC,Macdonald DR, Cairncross JG: A prospective study of short course RT in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 29: 835-839, 1994.
3. Thomas R, James N, Guerrero D, Ashley S, Gregor A, Brada M: Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high-grade glioma. Radiother Oncol, 33: 113-116, 1994.
4. Ford JM, Stenning SP, Boote DJ, Counsell R, Falk SJ, Flavin A, Laurence VM, Bleehen NM: A short fractionation radiotherapy treatment for poor prognosis patients with highgrade glioma. Clin Oncol (R Coll Radiol), 9: 20-24, 1997.
5. Hoegler DB, Davey P: A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol, 33:201-214, 1997.
6. McAleese JJ, Stenning SP, Ashley S, TraishD,Hines F, Sardell S, Guerrero D, BradaM: Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controls. Radiother Oncol, 67: 177-182, 2003.
7. RoaW, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol, 22: 1593-1598, 2004.
8. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, FrenayM, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY; Association of French-Speaking Neuro-Oncologists: Radiotherapy for glioblastoma in the elderly. N Engl J Med, 356: 1527-1535, 2007.
9. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD: Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer, 97: 2262-2266, 2003.
10. Chinot OL, Barrie M, Frauger E, Dufour H, Figarella- Branger D, Palmari J, Braguer D, Hoang-Xuan K,Moktari K, Peragut JC, Martin PM, Grisoli F: Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer, 100: 2208-2214, 2004.
11. Chamberlain MC, Chalmers L: A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol, 82: 207-209, 2007.
12. Minniti G, De Sanctis V, Muni R, Rasio D, Lanzetta G, Bozzao A, Osti MF, Salvati M, Valeriani M, Cantore GP, Maurizi Enrici R: Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol, 91: 95-100, 2009.
13. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG:Response criteria for phase II studies of supratentorialmalignant glioma. J Clin Oncol, 8: 1277-1280, 1990.
14. Mohan DS, Suh JH, Phan JL, Kupelian PA, Cohen BH, Barnett GH: Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys, 42: 981-987, 1998.
15. Villà S, Viñolas N, Verger E, Yaya R, Martínez A, Gil M, MorenoV, Caral L, Graus F: Efficacy of radiotherapy formalignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys, 42: 977-980, 1998.
16. Combs SE,Wagner J, Bischof M,Welzel T,Wagner F, Debus J, Schulz-Ertner D: Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys, 70: 987-992, 2008.
17. Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M, Osti MF, De Paula U, Lanzetta G, Tombolini V, Maurizi Enrici R: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol, 88: 97-103, 2008
18. Sijben AE, McIntyre JB, Roldán GB, Easaw JC, Yan E, Forsyth PA, Parney IF, Magliocco AM, Bernsen H, Cairncross JG: Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol, 89: 97-103, 2008.
19. Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A, Gardiman M, Scienza R, Monfardini S, Ermani M: A prospective study in glioblastoma multiforme. Cancer, 3: 657-662, 2003.
20. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R:MGMT gene silencing and benefit fromtemozolomide in glioblastoma. N Engl J Med, 352: 997-1003, 2005.
21. Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A: Temozolomide in radiochemotherapy combined treatment for newly-diagnosed glioblastomamultiforme: phase II clinical trial. Anticancer Res, 23: 5159-5164, 2003.